tpan.com Quick Links

2004 HIV Drug Guide

2004 HIV Services Directory

Positively Aware

Positively Aware en Español

New Drugs Coming Down the Pike

“Once” upon a time…the alarm clock had to be set every few hours, 24/7, as a reminder to take a dose of AZT. You got through it. Then came combination therapies, 12 pills at a time, three times a day, with food, plus a few others on an empty stomach a couple of hours later. You got through it. Then came along Crixivan every 8 hours or chewable Videx twice a day. Once again you got through it. Norvir liquid, enough said. At last, there is some good news. Once daily dosing is here for some drug products and just around the corner are quite a few more drugs.

Ideally, drugs that can be dosed once a day must be very potent, have minimal side effects, and should be “forgiving” for late or missed doses. In order to allow prescription drugs to be brought to market quicker, pharmaceutical companies file for Food and Drug Administra-tion (FDA) approval before dosing studies are finished. Once the drugs are on the market, they are still being studied in order to get approval for easier dosing. In some situations, clinicians can use pharmacokinetic (PK) data to make educated adjustments in dose and will prescribe drugs with “off label” directions. Basically, PK data tells us how much drug is in the blood and for how long. Blood levels need to be above a minimum level to be effective, but not too high as to cause toxic effects.

For example, because blood levels remain high for Viracept, it is now approved for twice daily dosing (5 tablets twice daily, instead of 3 tablets three times daily). Other times, the FDA rejects changes to originally approved dosing regimens, as in the case of Crixivan. Twice daily dosing of Crixivan did not show high enough levels of drug and the virus became resistant to the drug. Unless used in combination with other protease inhibitors, Crixivan is only approved for dosing every 8 hours, and never twice daily.

Before you get too excited about the possibility of leaving all your medicine at home and feeling free of the ball and chain, there are a few things you must know. If daily dosing were available, then each daily dose of the drug would become even more important. With adherence needing to be above the 95% level, even two missed doses per month could put you at risk for viral resistance and drug failure. It may also be important to be consistent with the time of the dose from day to day. The window for taking medication may not be much more flexible than 24 hours so drugs must be taken at the same time every day. The studies being conducted on once-a-day dosing regimens will address these issues, so don’t try this at home. Only your doctor can change the way to take your prescription drugs.

As mentioned, there is a large effort by the pharmaceutical companies to make taking the drug cocktails easier for people to handle. It has been shown that a simple regimen is easier to take and is effective for a longer period of time than more complex drug therapies. (Duh). But until once a day dosing is available, you’ll get through it.

Glen Pietrandoni is director of Clinical Pharmacy Services for the HIV-specialty Walgreens pharmacy located in the Howard Brown Health Center of Chicago.

Once-daily drugs available now

Sustiva

600 mg once daily approved; single 600 mg tablet soon

Videx (ddI)

400 mg once daily approved; 400 mg enteric coated tablet soon

Viramune

400 mg once daily being studied

Epivir (3TC)

300 mg once daily being studied

Crixivan/Norvir

1000 mg/100 mg or 1000 mg/200 mg once daily being studied

Fortovase/Norvir

1600 mg/100 mg once daily being studied


Once-daily drugs in research

Coviracil (FTC)

once daily nucleoside similar to 3TC

Lodanosine (F-dda)

once daily nucleoside similar to ddI

DOTC (BCH)

once daily nucleoside similar to 3TC

GW420867X

once daily nucleoside

Adefovir

once daily nucleotide, will not be available in the US

Tenofovir
(bis-POC PMPA)

once daily nucleotide, limited expanded access in the US

DPC 961 and DPC 963

once daily non-nucleoside. Phase III studies for DPC 961

PNU142721

one or two times daily non-nucleoside, related to delavirdine

BMS 232632

one or two times daily protease inhibitor, phase I/II

L-756,424

one or two times daily protease inhibitor, will be dosed with indinavir 1600 mg/800 mg once daily, or 800 mg/400 mg twice daily

T-1249

once daily second generation fusion inhibitor (sub-Q injection)


| Positively Aware | 2004 HIV Drug Guide | Positively Aware en español |

|Chicago Area HIV Services Directory | Publications Home |

| Publications | Client Services | MOCHA | Events | Helping TPAN |

| Contacts and Staff | About TPAN | Ask TPAN | Links | TPAN Home |